Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
NCT06215586 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 13, 2024
- Completion date
- September 2, 2025
- Enrollment
- 303 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, heart diseases, heart failure, heart failure preserved ejection fraction